Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharm Pharmacol ; 71(10): 1520-1531, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31385306

ABSTRACT

OBJECTIVE: This study proposed to use the nanotechnology to deliver glycoalkaloidic extract (AE) to bladder cancer cells, evaluating their activity in 2D and 3D models and the biological mechanism of cell death. METHODS: NPs were prepared by nanoprecipitation method using polylactic acid (PLA) and characterized considering their size, charge, particle concentration and stability. The cytotoxicity was evaluated in 2D and 3D model, and the apoptosis and cell cycle were investigated using flow cytometry. KEY FINDINGS: NPs loading AE (NP-AE) had diameter around 125 ± 6 nm (PdI <0.1) and negative charge. The encapsulation efficiency of SM and SS was higher than 85% for both compounds. The obtained formulation showed a significant in-vitro cytotoxic effect against RT4 cells in a dose-dependent manner with IC50 two fold lower than the free AE. The cytotoxic effect of NP-AE was mediated by apoptosis and cell cycle arrested in the S phase. RT4 cells cultured under 3D conditions exhibited a higher resistance to the treatments (IC50 ~ three fold higher than in 2D cell culture). CONCLUSION: The NP-AE might be a promising nanocarrier to load and deliver glycoalkaloids against bladder cancer.


Subject(s)
Alkaloids/chemistry , Alkaloids/pharmacology , Nanoparticles/chemistry , Plant Extracts/chemistry , Plant Extracts/pharmacology , Urinary Bladder Neoplasms/drug therapy , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Apoptosis/drug effects , Cell Cycle Checkpoints/drug effects , Cell Line, Tumor , Drug Carriers/chemistry , Humans , Nanotechnology/methods , Particle Size , Polyesters/chemistry , S Phase/drug effects , Urinary Bladder/drug effects
2.
Photochem Photobiol ; 89(5): 1176-84, 2013.
Article in English | MEDLINE | ID: mdl-23800045

ABSTRACT

We report the development of D, L lactic co-glycolic acid) (PLGA)-based nanoparticles (NPs) for topical delivery of protoporphyrin IX (PpIX), a photosensitizer (PS), in treatments like photodynamic therapy (PDT) of skin cancers. PpIX-NPs were obtained in ~75.0% yield, encapsulation efficiency of 67.7%, drug content of 50.3 µg mg(-1), average diameter of 290 nm maintained up to 30 days and a zeta potential of 32.3 mV. Sustained in vitro release of PpIX through artificial membranes following Higuchi kinetics was kept up to 10 days. In vitro retentions of PpIX both in stratum corneum (SC) and epidermis + dermis ([EP + D]) were higher from NPs (23.0 and 10.0 times, respectively) compared to control solutions at all times. Quantification of PpIX by extraction, after in vivo skin application of NPs-PpIX on hairless mice, showed higher retention of the PS both in SC and in [EP + D] (3.0 and 2.0 times, respectively) compared to control solutions. Taken together, the results indicate that NPs are suitable for PpIX encapsulation showing minimal permeation through the skin and a localized effect, characteristics of a potential and promising delivery system for PDT-associated treatments of skin cancers, photodiagnosis and their off-label uses.


Subject(s)
Drug Carriers , Lactic Acid/chemistry , Nanoparticles , Photosensitizing Agents/administration & dosage , Polyglycolic Acid/chemistry , Protoporphyrins/administration & dosage , Skin/metabolism , Animals , In Vitro Techniques , Mice , Mice, Hairless , Permeability , Photosensitizing Agents/pharmacokinetics , Polylactic Acid-Polyglycolic Acid Copolymer , Protoporphyrins/pharmacokinetics
3.
Gerodontology ; 29(4): 258-64, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22970792

ABSTRACT

OBJECTIVE: The aim of this work was to analyse qualitatively and quantitatively the newly formed bone after insertion of rhBMP-2 and protein extracted from Hevea brasiliensis (P-1), associated or not with a carrier in critical bone defects created in Wistar rat calvarial bone, using histological and histomorphometrical analyses. MATERIALS AND METHODS: Eighty-four male Wistar rats were used, divided into two groups, according to the period of time until the sacrifice (2 and 6 weeks). Each one of these groups was subdivided into six groups with seven animals each, according to the treatments: (1) 5 µg of pure rhBMP-2, (2) 5 µg of rhBMP-2/monoolein gel, (3) pure monoolein gel, (4) 5 µg of pure P-1, (5) 5 µg of P-1/monoolein gel and (6) critical bone defect controls. The animals were euthanised and the calvarial bone tissue removed for histological and histomorphometrical analyses. RESULT AND CONCLUSION: The results showed an improvement in the bone healing process using the rhBMP-2 protein, associated or not with a material carrier in relation to the other groups, and this process demonstrated to be time dependent.


Subject(s)
Bone Morphogenetic Protein 2/pharmacology , Hevea , Latex/pharmacology , Osteogenesis/drug effects , Plant Preparations/pharmacology , Skull/drug effects , Analysis of Variance , Animals , Drug Carriers , Glycerides/pharmacology , Latex/isolation & purification , Male , Models, Animal , Plant Preparations/isolation & purification , Rats , Rats, Wistar , Skull/cytology
4.
J Nanosci Nanotechnol ; 8(1): 340-7, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18468080

ABSTRACT

In this work we evaluated the photophysical and in vitro properties of Foscan, a second-generation photosensitizer drug (PS) widely used in systemic clinical protocols for cancer therapy based on Photodynamic Therapy (PDT). We employed biodegradable nanoemulsions (NE) as a colloidal vehicle of the oil/water (o/w) type focusing in topical administration of Foscan and other photosensitizer drugs. This formulation was obtained and stabilized by the methodology described by Tabosa do Egito et al., based on the mixture of two phases: an aqueous solution and an organic medium consisting of nonionic surfactants and oil. The photodynamic potential of the drug incorporated into the NE was studied by steady-state and time-resolved spectroscopic techniques. We also analyzed the in vitro biological behavior carried out in mimetic biological environment protocols based on the animal model. After topical application in a skin animal model, we evaluated the Foscan/NE diffusion flux into the skin layers (stratum corneum and epidermis + dermis) by classical procedures using Franz Diffusion cells. Our results showed that the photophysical properties of PS were maintained after its incorporation into the NE when compared with homogeneous organic medium. The in vitro assays enabled the determination of an adequate profile for the interaction of this system in the different skin layers, with an ideal time lag of 6 h after topical administration in the skin model. The Foscan diffusion flux (J) was increased when this PS was incorporated into the NE, if compared with its flux in physiological medium. These parameters demonstrated that the NE can be potentially applied as a drug delivery system (DDS) for Foscan in both in vitro and in vivo assays, as well as in future clinical applications involving topical skin cancer PDT.


Subject(s)
Emulsions , Mesoporphyrins/pharmacokinetics , Mesoporphyrins/therapeutic use , Nanotechnology , Photosensitizing Agents/pharmacokinetics , Photosensitizing Agents/therapeutic use , Skin Neoplasms/drug therapy , Skin/metabolism , Humans , In Vitro Techniques , Spectrometry, Fluorescence , Spectrophotometry, Ultraviolet
5.
Prostaglandins Other Lipid Mediat ; 83(1-2): 121-9, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17259078

ABSTRACT

Leukotriene B(4) (LTB(4)) is a potent inflammatory mediator and stimulates the immune response. In addition, LTB(4) promotes leukocyte functions such as phagocytosis, chemotaxis and chemokinesis of polymorphonuclear leukocytes, as well as modulates cytokine release. However, some physicochemical characteristics of leukotrienes, such as poor solubility in water and chemical instability, make them difficult to administer in vivo. The aim of this study was to develop LTB(4)-loaded microspheres (MS) that prolong and sustain the in vivo release of this mediator. An oil-in-water emulsion solvent extraction-evaporation method was chosen to prepare the lipid-loaded MS. We determined their diameters, evaluated the in vitro release of LTB(4), using enzyme immunoassay and evaluated in vitro MS uptake by peritoneal macrophages. To assess the preservation of neutrophil chemoattractant activity, LTB(4)-loaded MS were tested in vitro (in a modified Boyden microchamber) and in vivo, after intratracheal administration.


Subject(s)
Leukotriene B4/metabolism , Microspheres , Animals , Chemotaxis, Leukocyte/drug effects , Glycolates/metabolism , Humans , Inflammation , Lactic Acid , Leukotriene B4/administration & dosage , Leukotriene B4/pharmacology , Macrophages, Peritoneal/cytology , Macrophages, Peritoneal/drug effects , Macrophages, Peritoneal/metabolism , Male , Mice , Models, Theoretical , Neutrophils/cytology , Neutrophils/drug effects , Particle Size , Polyglycolic Acid , Polylactic Acid-Polyglycolic Acid Copolymer , Pulmonary Alveoli/drug effects , Pulmonary Alveoli/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...